U.S. Markets closed

CHF Solutions, Inc. (CHFS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5200-0.0236 (-4.34%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.5436
Open0.5260
Bid0.5185 x 2200
Ask0.5200 x 3000
Day's Range0.5056 - 0.5488
52 Week Range0.3000 - 2.9200
Volume5,149,051
Avg. Volume11,758,582
Market Cap23.453M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-1.2480
Earnings DateAug 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    CHF Solutions, Inc. Announces 14 Percent Increase in Revenue for Second Quarter 2020 Over Previous Quarter and Provides Company Update

    EDEN PRAIRIE, Minn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the second quarter ended June 30, 2020, which included the following highlights: * Revenue for the second quarter ended June 30, 2020, was $1.9 million, an increase of 14 percent from the first quarter of 2020 and 11 percent compared to the same period of the prior year. * Hosted two physician-led webinars on treatment of critically ill, COVID-19 patients, including a discussion of the publication SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill.1 which addressed the role of ultrafiltration in the treatment of COVID-19 patients. * Hosted a webinar led by Dr. David Askenazi, M.D. MSPH on treatment of fluid overload on pediatric patients. Announced partnership for a pediatric registry. * Announced the signing of a new a distribution arrangement to sell in the United Arab Emirates, effectively initiating presence in the Middle East. * Submitted a patent application for an adaptation of Aquadex SmartFlow™ system to rapidly clear cytokines. * Initiated a distribution agreement with Renal Sense, Ltd. to market and sell complementary real-time monitoring of patient’s renal function to prevent acute kidney injury. * Ended the quarter with $7.8 million in cash and no debt. During the quarter, closed on two registered direct offering for next proceeds of $3.4 million, and received $2.1 million from warrant exercises.“We continue to be very pleased that we produce a product that is providing a meaningful therapy for treating the COVID-19 patients,” said John Erb, chairman and CEO of CHF Solutions. “We know we are very fortunate to be less impacted than many small medical device companies, and although the rest of the year is full of uncertainty, we remain optimistic about the value we can bring to our customers and our investors.”The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 3591247. An audio archive of the webcast will be available following the call at http://ir.chf-solutions.com/events.About CHF Solutions CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the value that the company brings to its customers. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.1. https://pubmed.ncbi.nlm.nih.gov/32336959/FINANCIALS CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited, in thousands, except per share amounts)   Three months ended June 30,Six months ended June 30,   2020 2019  2020 2019  Net sales$1,863 $1,677 $3,493 $2,892  Costs and expenses:               Cost of goods sold 664  835  1,460  1,447    Selling, general and administrative 4,234  3,973  8,770  7,991    Research and development 885  1,297  1,749  2,607      Total costs and expenses 5,783  6,105  11,979  12,045      Loss from operations (3,920) (4,428) (8,486) (9,153)     Loss before income taxes (3,920) (4,428) (8,486) (9,153)   Income tax expense (2) (2) (4) (4) Net loss$(3,922)$(4,430)$(8,490)$(9,157)               Basic and diluted loss per share$(0.10)$(1.93)$(0.37)$(8.82)               Weighted average shares outstanding – basic and diluted 37,923  2,295  27,181  1,550                Other comprehensive loss:               Foreign currency translation adjustments$(2)$(3)$(5)$(5) Total comprehensive loss$(3,924)$(4,433)$(8,495)$(9,162) CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)  June 30, 2020  December 31, 2019  ASSETS (unaudited)     Current assets         Cash and cash equivalents  $7,821 $1,279    Accounts receivable 978  799    Inventory 2,789  1,797    Other current assets 141  161  Total current assets 11,729  4,036    Property, plant and equipment, net 1,042  991    Operating lease right-of-use asset 351  442    Other assets 21  133  TOTAL ASSETS$13,143 $5,602          LIABILITIES AND STOCKHOLDERS’ EQUITY       Current liabilities         Accounts payable$1,387 $1,488    Accrued compensation 1,695  1,592    Current portion of operating lease liability 196  186    Current portion of finance lease liability 17  —    Other current liabilities 40  85  Total current liabilities 3,335  3,351    Operating lease liability 160  261    Finance lease liability 46  —  Total liabilities 3,541  3,612          Commitments and contingencies               Stockholders’ equity       Series A junior participating preferred stock as of June 30, 2020 and December 31, 2019, par value $0.0001 per share; authorized 30,000 shares, none outstanding —  —  Series F convertible preferred stock as of June 30, 2020 and December 31, 2019, par value $0.0001 per share; authorized 435 and 535 shares, respectively, issued and outstanding 435 and 535, respectively —  —  Preferred stock as of June 30, 2020 and December 31, 2019, par value $0.0001 per share; authorized 39,969,565 and 39,969,465 shares, none outstanding —  —  Common stock as of June 30, 2020 and December 31, 2019, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 43,196,813 and 4,674,068, respectively 4  —  Additional paid‑in capital 234,381  218,278  Accumulated other comprehensive income:         Foreign currency translation adjustment 1,209  1,214  Accumulated deficit (225,992) (217,502) Total stockholders’ equity 9,602  1,990  TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$13,143 $5,602  CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (unaudited, in thousands)  Six months ended June 30,   2020  2019  Operating Activities:       Net loss$(8,490)$(9,157) Adjustments to reconcile net loss to cash flows used in operating activities:         Depreciation and amortization 151  120    Stock-based compensation expense, net 727  701    Loss on disposal of property and equipment 46  —  Changes in operating assets and liabilities:         Accounts receivable (179) (146)   Inventory (1,104) (32)   Other current assets 20  (75)   Other assets and liabilities 112  (18)   Accounts payable and accrued expenses (43) (267) Net cash used in operating activities (8,760) (8,874)         Investing Activities:         Purchases of property and equipment (69) (158) Net cash used in investing activities (69) (158)         Financing Activities:         Proceeds from public stock offerings, net 13,040  10,959    Proceeds from warrant exercises 2,340  —    Payments on finance lease liability (4) —  Net cash provided by financing activities 15,376  10,959          Effect of exchange rate changes on cash (5) (5) Net increase in cash and cash equivalents 6,542  1,922  Cash and cash equivalents - beginning of period 1,279  5,480  Cash and cash equivalents - end of period$7,821 $7,402          Supplemental cash flow information         Cash paid for income taxes$— $—    Inventory transferred to property, plant and equipment$112 $—    Equipment acquired through finance lease liability$67 $ —  CONTACT: CONTACTS: INVESTORS: Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

  • GlobeNewswire

    CHF Solutions Further Expands Commercial Presence in the Middle East with Distribution Arrangement for Israel and Palestine

    EDEN PRAIRIE, Minn., July 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with SysteMedic Ltd., covering Israel and Palestine, representing the second distribution partnership in the Middle East region.  Ultrafiltration therapy is now available in 16 countries outside the U.S. Ninety percent of hospitalizations among heart failure patients are due to signs and symptoms of fluid overload,1 and approximately two percent of the Israeli population suffers from heart failure.2  The Aquadex SmartFlow System is a simple, flexible and smart fluid management platform using ultrafiltration to stabilize patients experiencing fluid overload, giving providers the ability to manage their patients’ fluid balance with precision, control and ease.“CHF Solutions is committed to making ultrafiltration therapy available for patients throughout the world.  Our partnership with SysteMedic demonstrates continued execution on that strategy,” said John Erb, chairman and CEO of CHF Solutions. “Subject to regulatory approval, we look forward to working with SysteMedic to make the simple, flexible and smart Aquadex SmartFlow™ system available to patients in Israel and Palestine suffering from fluid overload due to heart failure, cardiovascular surgery and other critical care conditions.”“We are very excited to work with CHF Solutions to introduce their ultrafiltration technology to Israel and Palestine,” said Arik Yanco, General Manager of SysteMedic. “We believe the Aquadex therapy will make a difference in the quality of lives of patients and look forward to a successful partnership.”1 Costanzo MR et al. JACC. 2017;69(19):2428-45. 2 www.health.gov.il/PublicationsFiles/health2013.pdf.About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.About SysteMedicSysteMedic Ltd. was established in Israel in 2001, by a group of professionals, each with over 30 years of experience in a variety of clinical fields, including ICU, ER, OR, Trauma, Cardiology and Oncology, as well as related medical equipment and services. SysteMedic Ltd imports and markets innovative medical products and technologies to hospitals, private clinics, health services, home care, military and government customers in Israel and Palestine. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the growth and potential success of distribution partnerships outside of the U.S., including Israel and Palestine.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

  • GlobeNewswire

    CHF Solutions, Inc. To Announce Second Quarter 2020 Financial Results on August 4, 2020

    EDEN PRAIRIE, Minn., July 28, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the CHF Solutions website at http://ir.chf-solutions.com or access the webcast directly at http://ir.chf-solutions.com/events.  Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 3591247.  An audio archive of the webcast will be available following the call on the Investor page at http://ir.chf-solutions.com/events.About CHF SolutionsCHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012. CONTACT: CONTACTS: INVESTORS: Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com - MEDIA: Jessica Stewing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com